SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is trending following the announcement of a $1.4 billion debt exchange that converts convertible senior notes into common stock, sparking intense community debate over long-term balance sheet benefits versus immediate shareholder dilution. Investors remain sharply divided, with bulls viewing the move as a strategic cleanup of debt to facilitate future acquisitions, while bears and frustrated shareholders are criticizing management for the impact on equity value.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir Technologies is capturing significant attention as investors await the upcoming earnings report, with community discourse heavily polarized between long-term bullish conviction in its enterprise AI adoption and skepticism regarding its high valuation and recent stock price volatility. Market participants are intensely focused on the company's ability to maintain its rapid growth trajectory in commercial revenue and provide strong forward guidance to justify its premium multiple.

Snap, Inc. is a technology company, which engages in the provision of a visual messaging application that was created to help people communicate through short videos and images. The company was founded by Frank Reginald Brown IV, Evan Thomas Spiegel, and Robert C. Murphy in 2010 and is headquartered in Santa Monica, CA.

Snap Inc - Ordinary Shares - Class A

Snap Inc

Snap is trending as market participants weigh a potential speculative re-rating ahead of upcoming earnings, with community sentiment split between skepticism over leadership and excitement for the long-term potential of its AI-powered AR glasses. Traders are closely monitoring the stock's price action around key technical levels and debating whether the company's recent cost-cutting measures and product innovation will finally break the ongoing downward trend.

Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip Astley-Sparke, Colin A. Love, and Robert Coffin in March 2015 and is headquartered in Woburn, MA.

Replimune Group Inc

Replimune Group is surging following a positive 10-3 advisory committee vote regarding the clinical efficacy of its skin cancer therapy, sparking intense speculation about a potential short squeeze given the high short interest. While bulls anticipate a rally toward significant price levels, bears continue to cite concerns over the company's financial runway, potential dilution, and the risk that the FDA might still issue a third complete response letter despite the favorable committee sentiment.

Chevron Corp. engages in the provision of oil and gas energy solutions. It provides crude oil and natural gas, manufactures transportation fuels, lubricants, petrochemicals, and additives, and develops technologies that enhance business and the industry. It operates through the Upstream and Downstream segments. The Upstream segment consists of the exploration, development, and production of crude oil and natural gas, the liquefaction, transportation, and regasification associated with liquefied natural gas, the transporting of crude oil by major international oil export pipelines, the processing, transporting, storage, and marketing of natural gas, and a gas-to-liquids plant. The Downstream segment consists of the refining of crude oil into petroleum products, the marketing of crude oil and refined products, the transporting of crude oil and refined products by pipeline, marine vessel, motor equipment, and rail car, and the manufacturing and marketing of commodity petrochemicals and plastics for industrial uses and fuel & lubricant additives. The company was founded on September 10, 1879 and is headquartered in Houston, TX.

Chevron Corp.

Chevron is trending as investors weigh conflicting reports regarding potential Iran peace talks against ongoing global supply constraints. Community sentiment remains split between excitement over strong cash flow and dividends versus uncertainty about the durability of Middle East supply chain disruptions.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group is trending as investors react to the launch of a high-tier subscription service for Truth Social data, while the community remains sharply divided over the company's valuation, monetization potential, and the political rhetoric surrounding the firm's leadership.

Celsius Holdings, Inc. engages in the development, marketing, sale, and distribution of functional drinks and liquid supplements. It also offers post-workout functional energy drinks and protein bars. The company was founded in April 2004 and is headquartered in Boca Raton, FL.

Celsius Holdings Inc

Celsius Holdings is experiencing heightened volatility and intense social media debate as investors weigh the company's long-term growth potential against bearish concerns over margin pressure and sector-wide competition. The community remains deeply divided, with bulls pointing to robust brand loyalty and expansion efforts as a generational buying opportunity, while bears focus on recent price weakness and short-interest levels heading into earnings.

Algorand is a scalable, secure, and decentralized digital currency and smart contract platform. Its protocol uses a variation of Proof-of-Stake (PoS) called Pure PoS (PPoS) to secure the network and reach consensus on block production. Developers can build decentralized applications (dApps) using familiar programming languages, including Python, which Algorand supports natively. Its infrastructure enables various use cases, including payment systems, digital identity solutions, supply-chain tracking, and financial services. The protocol's architecture allows for tokenization of assets and the development of smart contracts, while its technical specifications support both retail users seeking basic transaction capabilities and enterprises requiring more, complex, blockchain solutions.

Algorand

Algorand is seeing increased market attention and social media buzz driven by a mix of long-term holders accumulating at recent lows and community excitement surrounding technical developments like quantum-resistant security. Investors are actively debating the potential for a trend reversal as volume builds and the asset continues to capture interest for its enterprise-ready blockchain infrastructure.

Pagaya Technologies Ltd. engages in the development of AI and data networks for the financial industry. Its product deploys data science, machine learning and AI technology to evaluate the customers' applications in real time. The company was founded by Gal Krubiner, Sanjiv Das, Yahav Yulzari, and Avital Pardo on March 20, 2016 and is headquartered in New York, NY.

Pagaya Technologies Ltd - Ordinary Shares - Class A

Pagaya Technologies Ltd

Pagaya is seeing significant trading volume and positive price momentum driven by strong institutional buying, a series of successful ABS deals, and growing investor optimism surrounding its profitability. The community is actively discussing the stock's undervaluation compared to fintech peers, with many focused on upcoming earnings and potential analyst upgrades as key catalysts for further growth.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TG Therapeutics is currently trending as investors debate the impact of strong Briumvi sales versus higher operating costs following a recent earnings report. The community remains highly bullish on the company's long-term pipeline, widely discussing the potential for a major buyout while dismissing current price volatility as orchestrated short-selling.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$ITRM because you type the pathogen before you run an IV according to an anesthesiologist I spoke with, (we could see hospital lab volume in the Dallas area when we were looking at buying several labs) you’ll know pathogen so no empirical use of Orly in cUTI step down. You’re matching the pathogen with the right drug, so in approximately 18 months if this closed tomorrow, a BP could be on their way to having Orly approved as cUTI step down therapy.. Like Fishman said: there’s a very well-known saying an infectious disease medicine: give the right patient the right drug at the right time- so on a step down therapy if you already know what pathogen patient has, you match the oral drug to the already identified bug-then the step down logically for any of the ESBL pathogens causing cUTIs will be to continue at home with Orlynvah- i’ve spoken with a couple doctors who said that they intend to do this off label for now. Challenge: FDA may protest this use and demand phase 3 study.

ALAS

Mr.Yoda

WindowShopper

Alex Bailey

StockTwits for iOS

Iterum Therapeutics Plc

 because you type the pathogen before you run an IV according to an anesthesiologist I spoke with, (we could see hospital lab volume in the Dallas area when we were looking at buying several labs) you’ll know pathogen so no empirical use of Orly in cUTI step down. You’re matching the pathogen with the right drug, so in approximately 18 months if this closed tomorrow, a BP could be on their way to having Orly approved as cUTI step down therapy.. Like Fishman said: there’s a very well-known saying an infectious disease medicine: give the right patient the right drug at the right time- so on a step down therapy if you already know what pathogen patient has, you match the oral drug to the already identified bug-then the step down logically for any of the ESBL pathogens causing cUTIs will be to continue at home with Orlynvah- i’ve spoken with a couple doctors who said that they intend to do this off label for now. Challenge: FDA may protest this use and demand phase 3 study.